Mesoblast Limited
HealthcareNASDAQ:MESO · NASDAQ Global Select
-$0.19 today
Vol 0.11M · Avg 0.21M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$17.2M of revenue converted into -$102.1M of net income for the selected period. Gross margin is -57.8% and net margin is -96.5%, showing how much revenue survives after costs and taxes. EPS is $-0.84, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.2M +191.4% | $5.9M -21.3% | $7.5M -26.5% | $10.2M +37.0% | $7.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $5.1M -87.5% | $41.1M -25.2% | $54.9M -13.6% | $63.6M -25.8% | $85.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $12.1M +134.3% | -$35.2M +25.8% | -$47.4M +11.1% | -$53.4M +31.8% | -$78.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 70.2% +666.0pp | -595.9% +36.3pp | -632.2% -109.6pp | -522.6% +527.2pp | -1049.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $34.8M +37.3% | $25.4M -6.8% | $27.2M -17.1% | $32.8M -38.1% | $53.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $39.3M +66.4% | $23.6M -55.5% | $53.1M -8.4% | $58.0M -8.8% | $63.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $74.5M +52.1% | $49.0M -36.2% | $76.8M -15.4% | $90.8M -21.1% | $115.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $6.4M +237.7% | $1.9M -53.9% | $4.1M -6.2% | $4.4M +2.7% | $4.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$73.7M -31.4% | -$56.1M +4.2% | -$58.5M +23.5% | -$76.6M +9.5% | -$84.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -428.3% +521.8pp | -950.1% -169.6pp | -780.6% -30.7pp | -749.9% +385.4pp | -1135.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$62.4M +25.8% | -$84.1M -21.4% | -$69.3M +14.0% | -$80.6M +26.1% | -$109.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -363.1% +1062.7pp | -1425.7% -502.0pp | -923.7% -134.6pp | -789.1% +674.1pp | -1463.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.6M +94.8% | $1.8M +119.5% | $831.0K | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $22.9M +11.0% | $20.7M +6.2% | $19.4M +12.5% | $17.3M +61.4% | $10.7M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$39.4M -884.2% | -$4.0M +68.8% | -$12.8M -22.3% | -$10.5M -210.7% | $9.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$101.8M -15.5% | -$88.1M -7.4% | -$82.1M +10.4% | -$91.6M +8.1% | -$99.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -592.0% +901.5pp | -1493.5% -399.0pp | -1094.5% -197.6pp | -896.9% +439.3pp | -1336.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $330.0K +272.8% | -$191.0K +9.9% | -$212.0K +11.3% | -$239.0K +70.8% | -$819.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$102.1M -16.1% | -$88.0M -7.4% | -$81.9M +10.4% | -$91.3M +7.6% | -$98.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -593.9% +896.4pp | -1490.3% -398.6pp | -1091.7% -197.1pp | -894.6% +430.7pp | -1325.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +5.6% | -$1 +9.2% | -$1 +24.6% | -$1 +18.8% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +5.6% | -$1 +9.2% | -$1 +24.6% | -$1 +18.8% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $120.8M +22.4% | $98.7M +17.8% | $83.8M +22.7% | $68.3M +12.8% | $60.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $120.8M +22.4% | $98.7M +17.6% | $83.9M +22.9% | $68.3M +12.9% | $60.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Galapagos N.V.
GLPG
$1.84B
uniQure N.V.
NASDAQ:QURE
$1.74B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MESO generate?
Mesoblast Limited (MESO) reported $17.20M of revenue in fiscal 2025.
Is MESO profitable?
Mesoblast Limited (MESO) reported -$102,142,000.00 of net income, with a net margin of -593.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.